Financial Data and Key Metrics Changes - Total revenues for Q4 2025 reached $1.51 billion, a 28% increase year-over-year, while full-year revenues totaled $5.14 billion, up 21% year-over-year [5][30] - Net sales in Q4 were $1.22 billion, representing a 20% increase compared to the prior year, with full-year net sales at $4.35 billion, also up 20% year-over-year [6][30] - GAAP R&D expenses for Q4 were $611 million, a 31% increase from the prior year, with full-year R&D expenses at $2.05 billion [30] - GAAP SG&A expenses for Q4 were $390 million, increasing 19% year-over-year, with full-year SG&A expenses at $1.38 billion, up 11% year-over-year [30] Business Line Data and Key Metrics Changes - Core business sales excluding Jakafi totaled $1.26 billion, a 53% increase versus 2024, with significant contributions from Opzelura, Niktimvo, and Monjuvi [6][10] - Jakafi sales in Q4 were $828 million, a 7% increase year-over-year, with full-year sales at $3.093 billion, an 11% increase [7] - Opzelura's Q4 net sales were $207 million, up 28%, with full-year sales at $678 million, a 33% increase [9] - Hematology and oncology product sales in Q4 were $187 million, up 121% year-over-year, with full-year sales at $583 million, an 83% increase [10] Market Data and Key Metrics Changes - The U.S. market for Opzelura in atopic dermatitis (AD) is growing at nearly 20% year-over-year, while the vitiligo market is growing in the mid-teens [46] - The pediatric launch of Opzelura AD is annualizing around $30 million, indicating strong market uptake [9][46] - The international sales for Opzelura in vitiligo doubled to $130 million in 2025, with expectations for continued growth [9] Company Strategy and Development Direction - The company aims to transition its core business and pipeline, with multiple assets moving from early to late-stage development, targeting MPNs, pancreatic cancer, colorectal cancer, and hidradenitis suppurativa (HS) [4][5] - The company anticipates significant growth in its core business, potentially matching Jakafi's current size by 2030, driven by upcoming product launches [13] - The company is focused on expanding its hematology portfolio and advancing novel therapies in myeloproliferative neoplasms [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting a strong foundation for an inflection point in 2026 and beyond [5] - The company expects total revenues for 2026 to be between $4.77 billion and $4.94 billion, representing a 10%-13% increase from the prior year [32] - Management emphasized the importance of execution in orchestrating product launches and managing multiple phase three trials [35] Other Important Information - The company has submitted regulatory applications for Jakafi XR, Opzelura for moderate AD, and povorcitinib for HS in Europe [5] - The company plans to initiate 14 pivotal trials across seven assets by the end of 2026, reflecting a robust pipeline [14][17] Q&A Session Summary Question: Thoughts on CALR pivotal programs and dosing strategies - Management is discussing dosing strategies with the FDA to address differential potency across CALR mutations and is confident in their approach [39][40] Question: Opzelura uptake and average usage - The AD business is growing at nearly 20% year-over-year, with significant contributions from the pediatric launch and international markets [46][47] Question: Monjuvi's opportunity in front-line DLBCL - Monjuvi is positioned as an addition to R-CHOP, with a focus on a broad patient population, and management is optimistic about its competitive edge [54][55] Question: Opzelura in PN and FDA recommendations - The FDA recommended an additional trial for Opzelura in PN due to mixed results from previous studies, but there is no read-through to HS [62][66] Question: Updates on mCALR bispecific and V617F programs - The mCALR bispecific program is accelerating, and management is optimistic about the V617F program's potential to address a significant patient population [72][75]

Financial Data and Key Metrics Changes - In Q4 2025, total revenues reached $1.51 billion, a 28% increase year-over-year, while full-year revenues totaled $5.14 billion, up 21% from the previous year [4][29] - Net sales for Q4 were $1.22 billion, representing a 20% increase compared to the prior year, with full-year net sales at $4.35 billion, also up 20% year-over-year [5][29] - R&D expenses for Q4 were $611 million, a 31% increase from the prior year, with full-year R&D expenses at $2.05 billion [29][30] - SG&A expenses for Q4 were $390 million, increasing 19% year-over-year, with full-year SG&A expenses at $1.38 billion, up 11% [29][30] Business Line Data and Key Metrics Changes - Core business sales excluding Jakafi totaled $1.26 billion, a 53% increase from 2024, with expectations for over 30% growth in 2026 [5][12] - Jakafi sales in Q4 were $828 million, an increase of 7% year-over-year, with full-year sales at $3.093 billion, representing an 11% increase [6][29] - Opzelura's Q4 net sales were $207 million, up 28%, with full-year sales at $678 million, a 33% increase [9][29] - Hematology and oncology product sales in Q4 were $187 million, up 121% year-over-year, with full-year sales at $583 million, an 83% increase [10][29] Market Data and Key Metrics Changes - The pediatric launch of Opzelura for atopic dermatitis is performing well, with annualized sales around $30 million [9] - International sales for Opzelura in vitiligo doubled to $130 million in 2025 [9] - The hematology and oncology business is expected to generate $800-$880 million in 2026, representing a 40%-50% increase compared to 2025 [12][29] Company Strategy and Development Direction - The company aims to transition its core business and pipeline, with multiple assets moving from early to late-stage development [3][4] - The focus is on expanding the core business, with expectations for product launches in late 2026 and early 2027 [12][14] - The company views business development as a multiplier to strengthen its core, with a focus on strategic fit and potential for durable revenue [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, with a revenue guidance for 2026 set at $4.77 billion-$4.94 billion, a 10%-13% increase from the prior year [31][32] - The company anticipates a significant increase in core business growth, with expectations for Jakafi sales to be between $3.22 billion and $3.27 billion in 2026 [31] - Management emphasized the importance of execution in orchestrating product launches and managing multiple phase three trials [32] Other Important Information - The company has submitted regulatory applications for Jakafi XR, Opzelura, and povorcitinib in Europe [4] - The pipeline has reached a new level of maturity, with 14 pivotal trials expected to be underway by the end of 2026 [15][16] Q&A Session Summary Question: Thoughts on CALR pivotal programs and dosing strategies - Management indicated that they will discuss dosing strategies with the FDA and are confident in their approach [36][39] Question: Opzelura uptake and average usage - Management noted that the AD business is growing at nearly 20% year-over-year, with significant growth expected in the pediatric segment [42][45] Question: Monjuvi's opportunity in front-line DLBCL - Management highlighted that Monjuvi is positioned as an addition to R-CHOP, with a competitive PFS benefit [47][51] Question: Opzelura in PN and FDA recommendations - Management clarified that the FDA recommended an additional trial for Opzelura in PN due to mixed results from previous studies, with no implications for HS [59][62] Question: mCALR bispecific and V617F program - Management expressed confidence in the mCALR bispecific program and the potential of the V617F program to deliver transformative clinical effects [64][68]

Incyte forecast annual sales below Wall Street estimates on Tuesday with its key growth driver Opzelura expected to underperform, raising concerns about the drugmaker's ability to offset looming patent losses on top-seller Jakafi. ...

03 R&D Highlights Pablo Cagnoni, MD | Head of R&D Alexis Smith | VP, Investor Relations 04 Financial Results Tom Tray | Principal Financial Officer 06 Q&A Fourth Quarter & Full-Year 2025 Financial & Corporate Update FEBRUARY 10, 2026 Agenda 01 Introduction Bill Meury | Chief Executive Officer 05 Closing Remarks Bill Meury | Chief Executive Officer Steven Stein, MD | EVP, Chief Medical Officer Dave Gardner | EVP, Chief Strategy Officer Mohamed Issa | EVP, Head of US Oncology 02 Opening Remarks Matteo Trotta ...

Financial Performance - Total revenue for Q4 2025 was $1.51 billion, a 28% increase year-over-year, and $5.14 billion for the full year 2025, a 21% increase year-over-year[1][6][7] - Total net product revenue for Q4 2025 was $1.22 billion, a 20% increase year-over-year, exceeding the full year 2025 guidance of $4.23 - $4.32 billion[1][7][11] - Total GAAP revenues for the quarter ended December 31, 2025, were $1.51 billion, representing a 28% increase compared to $1.18 billion in the same period of 2024[31] - Total net product revenues for the quarter increased 20% to $1.22 billion, driven by significant growth in Jakafi and Opzelura sales[32] - Product revenues for Q4 2025 reached $1,222.8 million, a 19.9% increase from $1,019.4 million in Q4 2024[75] - Total revenues for the twelve months ended December 31, 2025, were $5,141.2 million, up 21.3% from $4,241.2 million in 2024[75] - Net income for Q4 2025 was $299.3 million, a significant increase from $201.2 million in Q4 2024, representing a 48.8% growth[75] - Non-GAAP net income for Q4 2025 was $368.0 million, compared to $281.4 million in Q4 2024, marking a 30.7% increase[78] - Basic net income per share for Q4 2025 was $1.52, up from $1.04 in Q4 2024, reflecting a 46.2% increase[75] Revenue Guidance - Full year 2026 total net product revenue guidance is set at $4.77 - $4.94 billion, including Jakafi revenue of $3.22 - $3.27 billion and Opzelura revenue of $750 - $790 million[1][8][9] - Incyte's financial guidance for 2026 includes expectations for sales of Jakafi and Opzelura, along with anticipated revenue contributions from other hematology and oncology products like Niktimvo and Zynyz[71] Expenses - GAAP R&D expenses for the full year 2025 were $2.1 billion, a decrease of 21% compared to the prior year, while SG&A expenses were $1.4 billion, an increase of 11%[11] - Research and development expenses for Q4 2025 increased 31% to $611 million, primarily due to investments in late-stage development assets[37] - Selling, general, and administrative expenses for Q4 2025 rose 19% to $390 million, driven by costs associated with US oncology product launches[38] Cash and Assets - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $3.6 billion, up from $2.2 billion as of December 31, 2024[11] - Cash, cash equivalents, and marketable securities increased to $3,580.6 million as of December 31, 2025, up from $2,158.1 million in 2024[77] - Total assets grew to $6,958.0 million in 2025, a 27.7% increase from $5,444.3 million in 2024[77] - Stockholders' equity increased to $5,167.5 million in 2025, compared to $3,447.6 million in 2024, indicating a 49.9% growth[77] Clinical Trials and Regulatory Submissions - Incyte expects to have fourteen pivotal clinical trials underway by the end of 2025, reflecting strong pipeline progress[4] - The Company plans to file a supplemental Biologics License Application for tafasitamab in first-line DLBCL in the first half of 2026[12] - A regulatory decision for Jakafi XR is expected in mid-2026 following a response to the FDA's complete response letter[13] - The MAA for povorcitinib in hidradenitis suppurativa was submitted to the EMA at the end of 2025, with potential approval anticipated by the end of 2026[27] - Regulatory submissions and approvals are expected for Jakafi XR, Opzelura in Europe, Zynyz, Monjuvi, and povorcitinib[71] Product Highlights - Jakafi net product revenue for Q4 2025 was $828 million, a 7% increase year-over-year, with a total of $3.09 billion for the year, up 11%[32] - Opzelura net product revenue for Q4 2025 reached $207 million, a 28% increase, with annual revenue of $678 million, up 33%[32] - Jakafi is approved for multiple indications, including polycythemia vera and myelofibrosis, with a focus on patients who have had inadequate responses to other treatments[50] - Opzelura is the first and only treatment for repigmentation approved for nonsegmental vitiligo in the U.S., highlighting its unique market position[51] - Monjuvi has received accelerated approval for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma, expanding its therapeutic reach[56] - Pemazyre is approved for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma, showcasing its targeted treatment capabilities[59] - Niktimvo is a first-in-class therapy for chronic GVHD, currently being studied in combination trials, indicating ongoing innovation in treatment options[68] Other Financial Metrics - The company recorded a contract dispute settlement of $242.2 million for the year, reflecting the difference between accrued royalties and total payments to Novartis[39] - An asset impairment charge of $76.3 million was recorded in Q4 2025 related to downtown Wilmington properties[40] - The company reported milestone revenues of $100.0 million for Q4 2025, compared to $0 in Q4 2024[78]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Za ...

Core Viewpoint - Incyte Corporation (INCY) is expected to exceed revenue and earnings estimates for Q4 2025, with projected revenues of $1.35 billion and earnings of $1.94 per share [2][6]. Revenue Drivers - The primary revenue source for Incyte is the sales of its lead drug, Jakafi (ruxolitinib), which is anticipated to continue its strong performance across all approved indications [3][4]. - Jakafi's fourth-quarter sales are estimated at $799.3 million, with additional royalty revenues expected from Novartis due to higher Jakavi sales outside the U.S. [4][6]. - Other contributing factors to revenue include growth in Opzelura sales, which are projected at $196.5 million, and sales from other drugs like Minjuvi, Pemazyre, and Iclusig [8][12]. Recent Developments - Incyte's recent approval of Monjuvi for a new cancer indication is likely to enhance its sales, with the drug also receiving approval in the EU and Japan [10][12]. - The launch of Niktimvo, which recorded $45.8 million in sales in Q3 2025, is another significant development for the company [13][14]. Financial Performance - Incyte's stock has increased by 31.4% over the past six months, compared to the industry growth of 43.5% [5]. - The company has a mixed earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 14.35% [15]. Earnings Expectations - The Earnings Surprise Prediction model indicates a likelihood of an earnings beat for Incyte, with an Earnings ESP of +3.69% [16][17].

Core Insights - The report summarizes significant analyst rating adjustments that could influence market trends, highlighting both upgrades and downgrades across various companies [1]. Upgrades - B. Riley upgraded Snap (SNAP) from Neutral to Buy, maintaining a target price of $10, citing strong growth in high-end subscription revenue and the rollout of high-margin advertising formats [5]. - Seaport Research upgraded FuboTV (FUBO) from Neutral to Buy with a target price of $3, viewing current uncertainties as a quality investment opportunity following a significant stock drop post-earnings [5]. - Wolfe Research upgraded Zoom Video Communications (ZM) from Peer Perform to Outperform, setting a target price of $115, anticipating a re-acceleration in growth and strong performance in its contract center and phone business [5]. - Jefferies upgraded Celanese (CE) from Hold to Buy, raising the target price from $43 to $86, suggesting it is a good time to buy despite potential earnings volatility in the first half of 2026 [5]. - Cantor Fitzgerald upgraded DigitalOcean (DOCN) from Neutral to Overweight, increasing the target price from $47 to $68, emphasizing its focus on digital-native enterprises and a strong foundation for market expansion [5]. Downgrades - Stifel downgraded Microsoft (MSFT) from Buy to Hold, reducing the target price from $540 to $392, citing supply issues with Azure and strong competition from Google Cloud [5]. - Susquehanna downgraded Qualcomm (QCOM) from Positive to Neutral, lowering the target price from $210 to $140, recommending a wait-and-see approach due to industry challenges [5]. - Citigroup downgraded Six Flags Entertainment (FUN) from Buy to Neutral, cutting the target price from $25 to $20, citing overvaluation after a 40% increase since November [5]. - Jefferies downgraded Steven Madden (SHOO) from Hold to Underperform, lowering the target price from $37 to $30, highlighting ongoing pressures in its wholesale business [5]. - JPMorgan downgraded Corteva (CTVA) from Overweight to Neutral, raising the target price from $75 to $77, based on valuation considerations [5]. Initiations - Benchmark initiated coverage on Cava Group (CAVA) with a Buy rating and a target price of $80, recognizing its leading position in the Mediterranean dining category [5]. - H.C. Wainwright initiated coverage on Incyte (INCY) with a Buy rating and a target price of $135, noting potential catalysts that could stabilize revenue expectations post-Jakafi patent expiration [5]. - Bernstein initiated coverage on Coupang (CPNG) with an Underperform rating and a target price of $17, favoring companies with strong growth potential driven by online penetration [5]. - Benchmark initiated coverage on Andersons (ANDE) with a Buy rating and a target price of $75, highlighting the growth momentum in its ethanol business [5]. - Bank of America initiated coverage on Wave Life Sciences (WVE) with a Buy rating and a target price of $38, emphasizing the differentiated advantages of its obesity drug WVE-007 [6].

Incyte Corporation (NASDAQ:INCY) is one of the most undervalued quality stocks to buy right now. On January 13, TD Cowen raised its price target for Incyte to $128 from $101 with a Buy rating on the shares. The firm’s optimism follows Incyte’s presentation of a strategic roadmap aimed at potentially tripling its revenue, excluding Jakafi, by 2029. With several Phase 3 trial readouts and initiations scheduled, the firm views 2026 as a pivotal year for both execution and delivery for the company. Furthermo ...

Incyte Corp (NASDAQ:INCY) is one of the most undervalued stocks to buy and hold for 5 years. On January 27, Bank of America Securities analyst Tazeen Ahmad assigned a Buy rating to Incyte and set a $118 price target. This bullish ratings action stands in contrast to Wells Fargo’s downgrade of Incyte Corp (NASDAQ:INCY) to Equal Weight from Overweight on January 20. According to Wells Fargo, which also lowered the stock’s price target to $107 from $116, the downgrade reflects the company’s current valuation a ...